Cited 7 times in
Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이현철 | - |
dc.date.accessioned | 2014-12-20T17:11:53Z | - |
dc.date.available | 2014-12-20T17:11:53Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0969-7128 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/94142 | - |
dc.description.abstract | Diabetes is characterized by insulin resistance and a reduction in insulin secretion, leading to progressive β-cell failure and loss of β-cell mass. Its central therapeutic issues are how to restore glucose responsiveness of β-cells to normal and counteract defects in insulin secretion. Native glucagon-like peptide-1 (GLP-1), which makes β-cells competent and diabetic β-cells specifically more sensitive to glucose, has a major drawback of rapid inactivation. In this study, we describe the construction and analysis of a GLP-1 plasmid and double-stranded, adeno-associated viral (dsAAV) expression vector to overcome both the rapid degradation of native GLP-1 and limitations of gene therapy using standard single-stranded AAV. Our study results demonstrate that fasting blood glucose levels of db/db obese mice decreased significantly up to 4 months after a single injection of dsAAV GLP-1, and both insulin and circulating GLP-1 levels increased in dsAAV GLP-1-infected mice. These results demonstrate that dsAAV GLP-1 has long-term, efficient transgene expression with minimal toxicity and cellular immune responses. This study suggests that GLP-1 produced by dsAAV may be an alternative to the continuous infusions required for GLP-1 peptide therapy or daily injections of GLP-1. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 155~163 | - |
dc.relation.isPartOf | GENE THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Blood Glucose/analysis | - |
dc.subject.MESH | DNA* | - |
dc.subject.MESH | Dependovirus/genetics* | - |
dc.subject.MESH | Diabetes Mellitus, Experimental/therapy* | - |
dc.subject.MESH | GeneticTherapy/methods* | - |
dc.subject.MESH | Genetic Vectors | - |
dc.subject.MESH | Glucagon-Like Peptide 1/genetics* | - |
dc.subject.MESH | Glucagon-Like Peptide 1/metabolism | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Obese | - |
dc.title | Long-term, antidiabetogenic effects of GLP-1 gene therapy using a double-stranded, adeno-associated viral vector | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | S H Choi | - |
dc.contributor.googleauthor | H C Lee | - |
dc.identifier.doi | 10.1038/gt.2010.119 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03301 | - |
dc.relation.journalcode | J00924 | - |
dc.identifier.eissn | 1476-5462 | - |
dc.identifier.pmid | 20720576 | - |
dc.identifier.url | http://www.nature.com/gt/journal/v18/n2/full/gt2010119a.html | - |
dc.subject.keyword | glucagon-like peptide-1 | - |
dc.subject.keyword | GLP-1 | - |
dc.subject.keyword | diabetes | - |
dc.subject.keyword | adeno-associated virus | - |
dc.subject.keyword | dsAAV | - |
dc.contributor.alternativeName | Lee, Hyun Chul | - |
dc.contributor.affiliatedAuthor | Lee, Hyun Chul | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 18 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 155 | - |
dc.citation.endPage | 163 | - |
dc.identifier.bibliographicCitation | GENE THERAPY, Vol.18(2) : 155-163, 2011 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.